The AIDS epidemic is one of the deadliest pandemics in modern history, caused by the human immunodeficiency virus (HIV). Since it was first identified in 1981, HIV has infected tens of millions of people worldwide. As of 2024, roughly 40.8 million people are living with HIV globally, and 630,000 people died from AIDS-related illnesses that year alone.
How the Epidemic Began
On June 5, 1981, the CDC published a report describing five cases of a rare lung infection among previously healthy young men in Los Angeles. All five were gay men, and two had already died. That brief report marked the first official recognition of what would become the AIDS epidemic. Within months, similar clusters of unusual infections and rare cancers appeared in cities across the United States, and the syndrome soon surfaced on every continent.
The virus itself had been circulating for decades before that 1981 report. Scientists later traced HIV’s origins to central Africa, where a related virus in chimpanzees crossed into humans, likely in the early twentieth century. By the time medicine caught up, the virus had already spread widely through sexual contact, blood products, and shared needles.
The Difference Between HIV and AIDS
HIV and AIDS are not the same thing. HIV is the virus. AIDS is the late stage of infection that develops when the immune system has been severely damaged. Your immune system relies on a type of white blood cell called CD4 cells to fight off infections. HIV attacks and destroys those cells over time. A healthy person typically has 500 to 1,500 CD4 cells per cubic millimeter of blood. When that count drops to 200 or below, the diagnosis shifts from HIV to AIDS.
At that point, the immune system is so weakened that infections caused by bacteria, fungi, and viruses that a healthy body would easily handle can become life-threatening. These are called opportunistic infections, and before effective treatment existed, they were the primary cause of death in people with AIDS. Common examples include certain types of pneumonia, tuberculosis, and cancers like Kaposi sarcoma.
How HIV Spreads
HIV spreads through specific body fluids: blood, semen, vaginal fluids, rectal fluids, and breast milk. The risk varies dramatically depending on the type of exposure. Blood transfusion with infected blood carries the highest risk at roughly 9,250 transmissions per 10,000 exposures, though modern blood screening has made this route extremely rare in most countries. Sharing needles during injection drug use carries a risk of about 63 per 10,000 exposures.
For sexual transmission, receptive anal intercourse poses the greatest risk at about 138 per 10,000 exposures. Receptive vaginal intercourse carries a risk of about 8 per 10,000 exposures, while insertive vaginal intercourse is roughly 4 per 10,000. Oral sex, biting, spitting, and sharing sex toys carry negligible or very low risk. HIV does not spread through casual contact, sharing food, hugging, or breathing the same air.
Treatment Changed Everything
The first AIDS drug, AZT, was approved by the FDA in 1987. It slowed the virus but couldn’t stop it on its own, and side effects were severe. The real turning point came in the mid-1990s, when researchers developed a new class of drugs that could be combined with earlier medications. This combination approach, known as highly active antiretroviral therapy, attacked the virus at multiple stages of its life cycle simultaneously. AIDS-related deaths in the U.S. had exceeded 40,000 in 1995. After combination therapy became available, that number dropped rapidly.
Today, a person diagnosed with HIV who starts treatment early and takes it consistently can expect a near-normal lifespan. Treatment works by reducing the amount of virus in the blood to undetectable levels. And here’s the fact that reshaped how the world thinks about HIV: a person with an undetectable viral load has zero risk of transmitting HIV to sexual partners. This principle, often called “Undetectable equals Untransmittable” or U=U, is now supported by the CDC and backed by large clinical studies.
Globally, more than 77% of people living with HIV were receiving antiretroviral therapy in 2024. That’s enormous progress, but it still leaves millions without access to the drugs that could save their lives and prevent further transmission.
Prevention Tools Beyond Treatment
Prevention has expanded well beyond condoms, though condoms remain highly effective. PrEP, a medication taken by HIV-negative people before potential exposure, reduces the risk of getting HIV from sex by about 99% when taken as prescribed. Among people who inject drugs, PrEP pills reduce risk by at least 74%. PEP is a different approach: a short course of medication taken within 72 hours after a potential exposure to prevent infection from taking hold.
Newer injectable options are also entering the picture. A long-acting injectable drug that only needs to be administered twice a year has shown strong results in clinical trials. The challenge is cost. In the United States, the branded version of this drug costs around $28,000 per person per year for HIV treatment. New agreements with generic manufacturers aim to bring the prevention price down to roughly $40 per person per year in lower-income countries, a difference that illustrates both the promise and the inequality built into the global response.
The Global Toll
The AIDS epidemic has killed an estimated 42 million people since it began. In 2024, about 1.3 million people were newly infected with HIV, and 630,000 died from AIDS-related causes. While those numbers represent significant declines from the epidemic’s peak in the early 2000s, they also reflect a crisis that is far from over.
Sub-Saharan Africa has been hit hardest by far. The region accounts for a disproportionate share of the global burden, with women and girls facing particularly high rates of infection. Poverty, limited healthcare infrastructure, stigma, and gender inequality all fuel the epidemic in the most affected regions. Even in wealthier countries, HIV disproportionately affects marginalized communities, including men who have sex with men, transgender people, people who inject drugs, and racial minorities.
Why the Epidemic Continues
The tools to end the AIDS epidemic exist. Effective treatment prevents death and stops transmission. PrEP prevents new infections. Testing is widely available in many countries. Yet 1.3 million new infections in a single year shows that tools alone aren’t enough. Stigma still prevents people from getting tested or seeking care. In many parts of the world, laws criminalizing homosexuality or drug use push the most vulnerable people away from health services. Treatment access, while vastly improved, remains uneven. Roughly one in four people living with HIV worldwide is still not on treatment.
The gap between what science has made possible and what public health has actually delivered defines the current phase of the AIDS epidemic. It is no longer a mystery disease or an automatic death sentence. It is a manageable chronic condition for those who can access care, and a continuing catastrophe for those who cannot.